MicroRNA-1179 (miR-1179)

MicroRNA-1179 (miR-1179) is a short non-coding RNA (~22 nucleotides) that regulates gene expression after transcription by binding primarily to the 3'-untranslated regions (3'-UTRs) of target mRNAs, resulting in decreased translation or transcript degradation[6][7][8]. miR-1179 is frequently downregulated in several cancers, including glioblastoma, breast cancer, and papillary thyroid carcinoma, and functions predominantly as a tumor suppressor by inhibiting cell proliferation, inducing cell cycle arrest, and blocking cancer cell migration and invasion[1][2][3][4]. Direct targets include E2F transcription factor 5 (E2F5) and components of the Notch signaling pathway; as such, miR-1179 has been explored as a potential biomarker and therapeutic molecule for managing certain malignancies[1][2][3][4][5]. Its clinical utility is under investigation due to the general challenges associated with miRNA-based therapies, such as off-target effects and delivery specificity[6][8].

Other names

miR-1179MIR1179hsa-mir-1179MIRN1179mir-1179

Synthetic miRNA mimics or inhibitors (modulating miR-1179 levels to inhibit or restore function in cancer cells)[1][2]